Department of Error (DOI:10.1016/S0140-6736(06)68819-3);Good old warfarin for stroke prevention in atrial fibrillation

Lancet

Volumn 367, Issue 9526, 2006, Pages 1877-1878

  Verheugt, Freek WA ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; THROMBIN INHIBITOR; WARFARIN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; CLINICAL TRIAL; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 33744922618     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)68928-9     Document Type: Erratum

References (14)

1. Wolf P., Abbott R., and Kannel W. Atrial fibrillation: a major contributor to stroke. The Framingham Study. Arch Intern Med 147 (1987) 1561-1564
2. Lip G., Hart R., and Conway D. Antithrombotic therapy for atrial fibrillation. BMJ 325 (2002) 1022-1025
3. Verheugt F. Can we pull the plug for warfarin in atrial fibrillation?. Lancet 362 (2003) 1686-1687
4. CURE Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 345 (2001) 494-502
5. Steinhubl S., Berger P., Mann J., et al. Early and sustained dual antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288 (2002) 2411-2420
6. COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005) 1607-1621
7. ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 367 (2006) 1903-1912
8. SPAF Investigators. Adjusted dose warfarin versus low intensity fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: The Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet 348 (1996) 633-648
9. SPORTIF-III Investigators. Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation (SPORTIF-III): randomised controlled trial. Lancet 362 (2003) 1691-1698
10. Albers G., Diener H., Frison L., et al. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 293 (2005) 690-698
11. Diener H., Bogousslavsky J., Brass L., et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high risk patients (MATCH): a randomised, double-blind placebo-controlled trial. Lancet 364 (2004) 331-337
12. Bhatt D., Fox K., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354 (2006) 1706-1717
13. Van Es R., Jonker J., Verheugt F., Deckers J., and Grobbee D. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360 (2002) 109-113
14. Hurlen M., Abdelnoor M., Smith P., Erikssen J., and Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 347 (2002) 969-974